Compare KKR & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KKR | GSK |
|---|---|---|
| Founded | 1976 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.0B | 96.1B |
| IPO Year | 2010 | N/A |
| Metric | KKR | GSK |
|---|---|---|
| Price | $121.48 | $49.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 2 |
| Target Price | ★ $153.00 | N/A |
| AVG Volume (30 Days) | 3.3M | ★ 4.2M |
| Earning Date | 02-05-2026 | 02-09-2026 |
| Dividend Yield | 0.61% | ★ 3.41% |
| EPS Growth | N/A | ★ 118.57 |
| EPS | ★ 2.37 | 1.79 |
| Revenue | $22,245,686,000.00 | ★ $43,237,357,842.00 |
| Revenue This Year | N/A | $6.70 |
| Revenue Next Year | $32.10 | $5.10 |
| P/E Ratio | $51.23 | ★ $13.28 |
| Revenue Growth | N/A | ★ 2.73 |
| 52 Week Low | $86.15 | $32.38 |
| 52 Week High | $170.40 | $51.46 |
| Indicator | KKR | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 36.63 | 50.14 |
| Support Level | $122.66 | $47.62 |
| Resistance Level | $127.00 | $50.87 |
| Average True Range (ATR) | 4.61 | 0.82 |
| MACD | -1.44 | -0.24 |
| Stochastic Oscillator | 2.14 | 35.42 |
KKR is one of the world's largest alternative asset managers, with $723.2 billion in total managed assets, including $585.0 billion in fee-earning AUM, at the end of September 2025. The company has two core segments: asset management (which includes private markets—private equity, credit, infrastructure, energy, and real estate—and public markets—primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.